Showing results (371-380 of 502) with videos related to
Sort By:
Pageof 51
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2014
Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data BaseJohn L Mikell, Theresa W Gillespie, William A Hall, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2013
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancerSuresh S Ramalingam, Taofeek K Owonikoko, Madhusmita Behera, et al.Lung Cancer (Amsterdam, Netherlands)|July 16, 2013
A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancerS S Ramalingam, A Kotsakis, A A Tarhini, et al.The Lancet. Oncology|November 10, 2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trialJoel W Neal, Suzanne E Dahlberg, Heather A Wakelee, et al.Nature Communications|October 8, 2025
Non-canonical dihydrolipoyl transacetylase promotes chemotherapy resistance via mitochondrial tetrahydrofolate signalingJung Seok Hwang, JiHoon Kang, Jaehyun Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 9, 2019
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium ExperienceBadi El Osta, Madhusmita Behera, Sungjin Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung CancerSuresh S Ramalingam, Normand Blais, Julien Mazieres, et al.The Lancet. Respiratory Medicine|March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyNatasha B Leighl, Matthew D Hellmann, Rina Hui, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerSuresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, et al.Clinical Lung Cancer|January 27, 2018
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL TrialSuresh S Ramalingam, Maurice Pérol, Martin Reck, et al.Pageof 51